AKTS
BEARISH
$18.99
Live
Aktis Oncology, Inc. · NASDAQ
Target $31.25
(+64.6%)
$16.8
52W Range
$29.16
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$1.05B
P/E
N/A
ROE
-26.5%
Profit margin
N/A
Debt/Equity
0.05
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
AKTS exhibits weak financial health per the Piotroski F-Score of 3/9, indicating significant operational and profitability concerns, with negative margins, ROE, and ROA. The absence of an Altman Z-Score raises distress risk concerns, particularly given the company's negative earnings and extreme operating losses. Despite a strong analyst consensus of 'strong_buy' and a high target price, the stock trades at an inflated Price/Sales of 188.43 and lacks any intrinsic value anchor. The recent earnings surprises are volatile and predominantly negative, with a 101.51% average miss over the last four quarters, undermining credibility. The 15.2% decline across all time horizons further reflects persistent market skepticism.
Key Strengths
Analyst consensus is strongly bullish with a 'strong_buy' rating and a target price of $31.25, implying significant upside potential
Recent quarterly EPS growth shows strong momentum (+94.7% Q/Q, +85.2% YoY), suggesting improving earnings trajectory
Insider sentiment is moderately positive at 60/100, indicating some confidence among insiders despite no recent trades
Low debt/equity ratio (0.05) and high current/quick ratios (9.27, 9.18) signal strong liquidity and minimal leverage risk
Peer comparison shows AKTS is not alone in negative profitability, but its revenue growth and market cap position are competitive within biotech
Key Risks
Piotroski F-Score of 3/9 indicates poor financial health, with negative profitability, declining margins, and weak return metrics
No Altman Z-Score available, but the extreme operating margin (-1675.78%) and negative ROE (-26.50%) suggest high distress risk
Price/Sales of 188.43 is astronomically high, indicating the stock is priced for perfection and highly sensitive to growth disappointment
Earnings surprises are consistently negative (average -101.51% over last 4 quarters), eroding investor trust and signaling poor forecasting accuracy
No dividend, no free cash flow, and no P/E or PEG ratios make traditional valuation models inapplicable, increasing reliance on speculative growth assumptions
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
29
Weak
25
68
30
20
0
AI Verdict
Weak
Key drivers: Low Piotroski F-Score (3/9), Extreme negative profitability and margins, Lack of intrinsic value or Graham Number, High Price/Sales multiple, Negative earnings surprises
Confidence
88%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- Low debt/equity ratio (0.05) supports financial stability
- High current and quick ratios (9.27, 9.18) indicate strong liquidity
Watchpoints
- No Graham Number or intrinsic value estimate available
- Price/Sales of 188.43 is extremely high relative to peers
- No P/E or PEG ratios available, making valuation speculative
Future
68/100
Ref Growth rates
Positives
- Strong Q/Q and YoY EPS growth (+94.7% and +85.2%)
- Analyst target price of $31.25 implies 64.4% upside from current price
- Recent earnings beat (2024-11-14) with +53.9% surprise
Watchpoints
- Average earnings surprise of -101.51% over last 4 quarters
- High growth expectations are not supported by current profitability
- Revenue growth metrics are missing, limiting forward assessment
Past
30/100
Ref Historical trends
Positives
- Some historical earnings beats (e.g., 2024-11-14, 2023-02-07)
- Consistent EPS reporting across 25 quarters shows operational continuity
Watchpoints
- Persistent negative earnings and operating losses
- Negative ROE (-26.50%) and ROA (-14.80%) over multiple periods
- Extreme operating margin of -1675.78% indicates severe inefficiency
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt/equity (0.05) and high liquidity ratios
- No debt obligations reported
Watchpoints
- Piotroski F-Score of 3/9 indicates weak financial health
- No Altman Z-Score available, but negative ROE and margins suggest distress risk
- Negative operating cash flow and no free cash flow
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- No history of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$18.99
Analyst Target
$31.25
Upside/Downside
+64.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AKTS and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AKTS
Aktis Oncology, Inc.
Primary
|
-15.2% | -15.2% | -15.2% | -15.2% | +5.2% | +1.0% |
|
KMTS
Kestra Medical Technologies, Ltd.
Peer
|
-18.2% | -18.2% | -26.2% | -18.8% | -19.3% | -9.9% |
|
PNTG
The Pennant Group, Inc.
Peer
|
-26.0% | +129.2% | +16.1% | +27.2% | -7.9% | -4.0% |
|
ABCL
AbCellera Biologics Inc.
Peer
|
-90.7% | -53.9% | +45.4% | -21.9% | +11.5% | +1.2% |
|
PCRX
Pacira BioSciences, Inc.
Peer
|
-62.4% | -44.9% | -2.5% | +4.8% | +8.8% | +0.2% |
AKT
Aktis Oncology, Inc.
Primary
5Y
-15.2%
3Y
-15.2%
1Y
-15.2%
6M
-15.2%
1M
+5.2%
1W
+1.0%
KMT
Kestra Medical Technologies, Ltd.
Peer
5Y
-18.2%
3Y
-18.2%
1Y
-26.2%
6M
-18.8%
1M
-19.3%
1W
-9.9%
PNT
The Pennant Group, Inc.
Peer
5Y
-26.0%
3Y
+129.2%
1Y
+16.1%
6M
+27.2%
1M
-7.9%
1W
-4.0%
ABC
AbCellera Biologics Inc.
Peer
5Y
-90.7%
3Y
-53.9%
1Y
+45.4%
6M
-21.9%
1M
+11.5%
1W
+1.2%
PCR
Pacira BioSciences, Inc.
Peer
5Y
-62.4%
3Y
-44.9%
1Y
-2.5%
6M
+4.8%
1M
+8.8%
1W
+0.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-11.02
PEG Ratio
N/A
P/B Ratio
-0.12
P/S Ratio
188.43
EV/Revenue
11.46
EV/EBITDA
-0.9
Market Cap
$1.05B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-1675.78%
Gross Margin
N/A
ROE
-26.5%
ROA
-14.8%
Growth
Revenue and earnings growth rates
Revenue Growth
N/A
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.05
Low debt
Current Ratio
9.27
Strong
Quick Ratio
9.18
Excellent
Cash/Share
$364.59
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2024
Revenue
$0.0B
Op. Margin
-1675.8%
Net Margin
-1292.2%
Total Assets
$0.3B
Liabilities
$0.4B
Equity
$-0.1B
Debt/Equity
-4.71x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
117%
Quarterly Earnings History
EPS performance vs analyst estimates
2024-11-14
$-0.04
+53.9% surprise
2024-10-08
$-0.75
-435.7% surprise
2024-05-13
$-0.14
-18.6% surprise
2024-02-13
$-0.19
-5.6% surprise
Healthcare Sector Comparison
Comparing AKTS against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-26.5%
This Stock
vs
-88.14%
Sector Avg
-69.9%
(Below Avg)
Debt to Equity
0.05
This Stock
vs
2.66
Sector Avg
-98.2%
(Less Debt)
Current Ratio
9.27
This Stock
vs
4.47
Sector Avg
+107.1%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AKTS
Aktis Oncology, Inc.
|
BEARISH | $1.05B | - | -26.5% | -% | $18.99 | |
|
KMTS
Kestra Medical Technologies, Ltd.
|
BEARISH | $1.04B | - | -92.7% | -173.0% | $17.87 | Compare |
|
PNTG
The Pennant Group, Inc.
|
BULLISH | $1.06B | 36.21 | 9.8% | 3.1% | $30.42 | Compare |
|
ABCL
AbCellera Biologics Inc.
|
NEUTRAL | $1.06B | - | -14.5% | -194.9% | $3.49 | Compare |
|
PCRX
Pacira BioSciences, Inc.
|
BEARISH | $1.03B | 149.12 | 1.0% | 1.0% | $23.86 | Compare |
AKTS
Aktis Oncology, Inc.
BEARISH
Mkt Cap
$1.0B
P/E
-
ROE
-26.5%
Price
$18.99
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-12 | GADICKE ANSBERT S. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 1,112,777 | $20,029,986 |
| 2026-01-12 | GADICKE ANSBERT S. | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 8,805,578 | - |
| 2026-01-12 | SEGAL LLOYD MITCHELL | Director | Stock Award | 19,631 | - |
| 2026-01-12 | FOLEY TODD | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | 232,870 | $4,191,660 |
| 2026-01-12 | FOLEY TODD | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 4,002,533 | - |
| 2026-01-12 | KIM HELEN SUSAN | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | 835,000 | $15,030,000 |
| 2026-01-12 | KIM HELEN SUSAN | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 4,994,212 | - |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 1,112,777 | $20,029,986 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 8,805,578 | - |
| 2026-01-12 | ECOR1 CAPITAL, L.L.C. | Unknown | Purchase | 2,222,222 | $39,999,996 |
| 2026-01-12 | ECOR1 CAPITAL, L.L.C. | Unknown | Stock Award | 2,602,247 | - |
| 2026-01-12 | VIDA VENTURES II, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Purchase | 835,000 | $15,030,000 |
| 2026-01-12 | VIDA VENTURES II, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 4,994,212 | - |
GADICKE ANSBERT S.
Beneficial Owner of more than 10% of a Class of Security
2026-01-12
1,112,777 shares
·
$20,029,986
GADICKE ANSBERT S.
Beneficial Owner of more than 10% of a Class of Security
2026-01-12
8,805,578 shares
SEGAL LLOYD MITCHELL
Director
2026-01-12
19,631 shares
FOLEY TODD
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-12
232,870 shares
·
$4,191,660
FOLEY TODD
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-12
4,002,533 shares
KIM HELEN SUSAN
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-12
835,000 shares
·
$15,030,000
KIM HELEN SUSAN
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-12
4,994,212 shares
MPM BIOVENTURES 2018, L.P.
Beneficial Owner of more than 10% of a Class of Security
2026-01-12
1,112,777 shares
·
$20,029,986
MPM BIOVENTURES 2018, L.P.
Beneficial Owner of more than 10% of a Class of Security
2026-01-12
8,805,578 shares
ECOR1 CAPITAL, L.L.C.
Unknown
2026-01-12
2,222,222 shares
·
$39,999,996
ECOR1 CAPITAL, L.L.C.
Unknown
2026-01-12
2,602,247 shares
VIDA VENTURES II, L.L.C
Beneficial Owner of more than 10% of a Class of Security
2026-01-12
835,000 shares
·
$15,030,000
VIDA VENTURES II, L.L.C
Beneficial Owner of more than 10% of a Class of Security
2026-01-12
4,994,212 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
4 analysts
HC Wainwright & Co.
2026-03-09
Buy
Leerink Partners
2026-02-03
Outperform
JP Morgan
2026-02-03
Overweight
Past News Coverage
Recent headlines mentioning AKTS from our newsroom.
Newest → oldest
No matching news yet.